The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

2-Year U.S. Treasury Note Continuous Contract $103.594 0.059 0.06% 5-Year U.S. Treasury Note Continuous Contract $108.164 0.148 0.14% 10-Year U.S. Treasury Note Continuous Contract $111.359 0.188 ...

With over 10 million people affected worldwide, Parkinson's disease is the fastest-growing neurological disorder. More than ...

After hours: March 21 at 7:59:34 PM EDT Loading Chart for AI ...

Realme started 2020 with a budget smartphone called the Realme 5i, and hot on its tail, the company is bringing in yet another very affordable smartphone called the Realme C3. The C series is Realme's ...

After hours: March 19 at 7:59:25 PM EDT ...

Elvira, IV3FSG will be active as D68Z from Moroni, Comoro Islands, IOTA AF - 007, 28 February - 1 April 2025.